FFF Enterprises: BioSupply Trends Newsletter
Wednesday, Jan 25, 2017

CDC Changes Recommendation for HPV Vaccine for Children


In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly

In October, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) changed its recommendation for girls and boys to receive only two doses, versus three, of the human papilloma virus (HPV) vaccine prior to age 15. ACIP’s decision was based on results of numerous studies showing that in the younger group, the two-dose vaccine was just as protective, and even slightly more so, than the three-dose series. [ read more ]

IVIG Treatment May Lead to Poorer Outcomes
in GBS Patients

A new study shows that individuals treated with intravenous immune globulin for Guillain-Barré syndrome (GBS) are at increased risk of developing hypoalbuminemia (reduced albumin levels), which may result in a more severe disease course and worse outcome. [ read more ]

Kedrion Terminates Sale of Bivigam IVIG for 2017

Due to unexpected difficulties in the manufacture of Bivigam (10% intravenous immune globulin [human]), it will no longer be available for sale in the U.S. as of March 1. In light of this recent information regarding Bivigam 10%, FFF Enterprises is ready to help with IG options through biosupply.fffenterprises.com or Wow! Customer Care at (800) 843-7477. [ read more ]

Industry News


From Octapharma

Octapharma made a charitable donation of 4.5 million units of its fourth-generation, human cell-line-derived recombinant factor VIII product, Nuwiq, to the World Federation of Hematology (WFH) Humanitarian Aid Program. [ read more ]

From Moffitt Cancer Center

Researchers at the Moffitt Cancer Center are developing a new vaccine that will help early-stage breast cancer patients who have HER2 positive disease.  [ read more ]

From Kawasaki Disease Foundation of India

The Kawasaki Disease Foundation of India has launched the world’s first free mobile app on Kawasaki disease. The app can be downloaded from the Google Play store. [ read more ]

IVIG & Albumin Supply Index


What's New at FFF

Bivalirudin (Fresenius Kabi)

Bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients 1) with unstable angina undergoing percutaneous transluminal coronary angioplasty; 2) undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa inhibitor as in the REPLACE-2 study; and 3) with, or at risk of, heparin-induced thrombocytopenia or heparin-induced thrombocytopenia and thrombosis syndrome, undergoing PCI. It is available for intravenous use, and is supplied in a single-use vial containing 250 mg of Bivalirudin. It is intended for use with aspirin, and has been studied only in patients receiving concomitant aspirin.

For more information about Bivalirudin, login to biosupply.fffenterprises.com
*Call for eligibility through your GPO affiliation.

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective January 1, 2017, through March 31, 2017.

Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
Bivigam J1556 $74.29 $73.10
Carimune NF J1566 $64.08 $63.05
Flebogamma J1572 $65.36 $64.31
Gammagard S/D J1566 $64.08 $63.05
Gammaplex J1557 $78.01 $76.76
Octagam J1568 $70.80 $69.66
Privigen J1459 $77.35 $76.11
Cuvitru J3490 / J3590 / J7799 ** **
Hizentra J1559 $98.46 $96.88
HyQvia J1575 $129.69 $127.61
Gammagard Liquid J1569 $80.39 $79.10
Gammaked J1561 $72.88 $71.71
Gamunex-C J1561 $72.88 $71.71

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.
** Cuvitru does not yet have Medicare rates.



FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2017 FFF Enterprises, Inc.
This email was sent by: %%Member_Busname%%, %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
Manage preferences: Privacy Policy, Update Profile, Unsubscribe.